Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Stifel Nicolaus analyst Dae Gon Ha maintained a Hold rating on Prime Medicine, Inc. (PRME – Research Report) today. The company’s ...

Former prime minister Boris Johnson has said he believes the Covid pandemic was caused by a leak from a laboratory in China, ...

N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios ...

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

You probably enjoy getting free shipping, Prime Video and Prime Day deals. To take full advantage of your Prime membership, ...

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...

Consumer staples shares jumped by 0.3% on Monday. In trading on Monday, materials shares fell by 0.6%. In commodity news, oil ...

Prime Medicine and Bristol Myers Squibb are collaborating on next-generation ex vivo T-cell therapies. Read more here.

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.